Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

International Prize for VTT's Allergy Vaccine Development Work

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
First vaccines to be ready for launch in about five years.

The European Association of Research and Technology Organizations EARTO has awarded VTT Technical Research Centre of Finland an innovation prize for the technological development work behind allergy vaccine.

VTT patented technology helps the human body to develop resistance to allergens. The award ceremony was held in Brussels on Wednesday 4 December. VTT also has last year's EARTO innovation prize for its bio-oil production process.

VTT spin-off Desentum Ltd is responsible for developing and commercializing new generation allergy vaccines based on VTT technology. The first vaccines will be ready for launch in about five years.

“The innovation behind the allergy vaccine is a good example of just how significant the impact of science and technology on society can be. This is the second time EARTO has awarded VTT its innovation prize. Considering EARTO has around 300 member organizations, winning the prize in two consecutive years speaks volumes for the high level and impact of our research and development work,” says Johanna Buchert, Vice President, Strategic Research, VTT.

VTT's patents are based on application of gene technology to alter the structure of an allergen - a protein causing allergy – so that it will cause fewer allergic symptoms while remaining effective in desensitization therapy.

The foundation for the development work rests on a scientific breakthrough made in a cooperation project involving VTT, the University of Eastern Finland and HUCH Skin and Allergy Hospital.

Research scientists were able to determine how an IgE antibody binds an allergen, and were the first to present a detailed 3D structure. The complex proved to be different from that anticipated by scientists around the world.

Desentum Ltd, the VTT spin-off responsible for the development and commercialization of the allergy vaccine, plans to start phase I clinical trials within a year. The first allergy vaccines could enter the market in about five years. These are expected to alleviate the symptoms of common allergies such as pollen, animal and food allergies.

According to estimates, allergies are among the top five costliest disease groups in industrialized countries. The estimated number of people suffering from allergies in Europe is more than 80 million, with 65 million in the US.

Allergic rhinitis affects around 25 per cent of the European population. The estimated market for the new allergy vaccines is approximately EUR 366 million in Europe and approximately USD 700–800 million worldwide.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!